Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).-MedSci.cn

Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).

Barlesi, F; Goldberg, SB; Mann, H; Gopinathan, A; Newton, MD; Aggarwal, C

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务